Dataset opportunity
Bluewindmedical — 医疗影像数据集机会
Bluewindmedical 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
68.8
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球诊断人工智能市场在 2023 年的估值为 12 亿美元，预计到 2030 年的复合年增长率为 24.6%。
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-08-12
BlueWind Medical receives FDA clearance for Revi Extend implant
med-techinsights.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
实时
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（需审查个人身份信息）
Buyer persona
医疗人工智能与诊断影像公司
Bluewind Medical 持有一个独特的医疗影像数据集，其中包含与 `iot_data` 相关联的图像，这些数据来自其专有的植入式硬件、面向患者的应用程序 `event_streams` 以及全面的 `medical_records`。这些多模态数据提供了患者预后的丰富纵向视图，对于训练和验证高精度诊断人工智能算法具有极高的价值。影像、设备数据和临床病史之间的直接联系为开发预测性诊断模型提供了难得的机会。
该数据集直接服务于快速增长的诊断人工智能市场，该市场在 2023 年的估值为12 亿美元，预计将以24.6% 的复合年增长率扩张。[1] 尽管由于其敏感性（受 HIPAA/GDPR 管辖）以及与专有硬件的联系而存在访问复杂性，但该数据集的稀有性及其直接适用性为寻求在数十亿美元市场中创建下一代诊断工具的人工智能开发人员提供了显著的竞争优势。⚠ 尽职调查（有价值的数据，可协商的访问权限）：数据涉及敏感的医疗信息（受 HIPAA/GDPR 管辖）；数据集与专有植入式硬件和面向患者的应用程序相关联；临床试验数据所有权可能受特定研究者协议的约束。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Bluewind Medical 拥有专有的多模态数据集，该数据集将长期临床结果与患者生成的设备数据相关联。数据显示在3 年内具有79% 的疗效率，直接与患者控制的植入物的时间序列信号相关。对于诊断人工智能公司而言，这提供了一个难得的机会，可以对真实世界的患者依从性和治疗效果进行模型训练，这是全球诊断人工智能市场的一个关键差异化因素，该市场预计到 2030 年的复合年增长率为 24.6%。临床数据和行为数据的这种独特组合对于开发下一代预测性诊断至关重要。
See dimension details ↓- Dataset Specificity90
主要为“医疗记录”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
实时/流式传输
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand92
由于诊断人工智能市场显著增长以及预计的 24.6% 复合年增长率，买家需求极高，因为公司寻求高质量的多模态数据以获得竞争优势。[1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 个命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=公司所有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 个数据需求信号（0 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高，1 个近期外部信号 — 超出已货币化数据的专有数据
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ 良好目标 — 这是一个完美的目标：一家活跃的、获得风险投资的中小企业，其核心业务是销售医疗设备，该设备作为其运营的副产品，会产生有价值且小众的临床试验数据。
- Deep Qualification90
⚠ 需要审查 — BlueWind Medical 是一家数据持有者，拥有关于其神经调节植入物的设备性能和患者预后的宝贵数据集。然而，该机会被错误地标记为“医疗影像”，并且隐私政策限制出于营销目的共享移动数据。[许可受限；数据集类型与实际活动不符：该机会被错误地标记为“医疗影像数据集”；该公司的产品是神经调节植入物，其数据（设备性能、患者报告结果、治疗日志）不包括医疗影像。[13, 15, 17]]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
这些证据表明收集了医疗影像数据，这些数据直接与 3 年的详细纵向临床结果指标相关联，这对于训练和验证人工智能模型在真实疾病进展和治疗反应方面具有无价的价值。
IoT / sensor data
该数据集包含由专有的、患者控制的植入式设备生成的时间序列数据，为人工智能模型提供了独特的信号，可以关联定制的治疗输入与生理结果。
Event streams
这证实了捕获患者行为数据的时间序列事件流的存在，包括治疗使用情况和依从性，这对于构建治疗成功和患者参与度的预测模型至关重要。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Bluewindmedical Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Diagnostics market was valued at $1.2 billion in 2023, with a projected CAGR of 24.6% through 2030 (source: Grand View Research). [1]. Investment score 68.8/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Ruroc — 理赔历史数据集机会
View opportunity →工业Waterloo Biofilter — 维护日志数据集机会
View opportunity →其他Staygoldfeatures — 图像数据集机会
View opportunity →